Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FLGT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGTFulgent Genetics$20.36-0.2%$19.62$14.57▼$24.61$623.22M0.83380,825 shs224,313 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGTFulgent Genetics0.00%+9.88%+5.66%+1.19%-14.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFLGTFulgent Genetics3.6398 of 5 stars2.32.00.04.12.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLGTFulgent Genetics 2.67Moderate Buy$25.3324.43% UpsideCurrent Analyst Ratings BreakdownLatest FLGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025FLGTFulgent GeneticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$20.00 ➝ $30.008/4/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$23.00 ➝ $21.00(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLGTFulgent Genetics$283.47M2.20N/AN/A$36.92 per share0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLGTFulgent Genetics-$42.71M-$1.66N/AN/AN/A-16.83%-2.26%-2.10%N/ALatest FLGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/1/2025Q2 2025FLGTFulgent Genetics-$0.23$0.07+$0.30-$0.62$76.21 million$81.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFLGTFulgent GeneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLGTFulgent GeneticsN/A6.016.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLGTFulgent Genetics48.06%Insider OwnershipCompanyInsider OwnershipFLGTFulgent Genetics33.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFLGTFulgent Genetics1,31330.61 million20.47 millionOptionableFLGT HeadlinesRecent News About These CompaniesXTX Topco Ltd Takes $324,000 Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)4 hours ago | marketbeat.comFulgent Genetics (FLGT) Receives a Hold from Piper SandlerAugust 9 at 4:06 PM | theglobeandmail.comFulgent Genetics (NASDAQ:FLGT) Upgraded to Buy at UBS GroupAugust 8 at 2:25 AM | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Given a $21.00 Price Target by Piper Sandler AnalystsAugust 7, 2025 | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Shares Up 9.3% - Here's WhyAugust 6, 2025 | marketbeat.comFulgent Genetics (NASDAQ:FLGT) Raised to "Buy" at UBS GroupAugust 6, 2025 | marketbeat.comUBS Upgrades Fulgent Genetics (FLGT)August 6, 2025 | msn.comFulgent Genetics (NASDAQ:FLGT) Shares Down 3.4% Following Analyst DowngradeAugust 5, 2025 | marketbeat.comFulgent Genetics (NASDAQ:FLGT) Price Target Lowered to $21.00 at Piper SandlerAugust 5, 2025 | marketbeat.comFulgent Genetics (NASDAQ:FLGT) Shares Down 3.4% on Analyst DowngradeAugust 5, 2025 | americanbankingnews.comFulgent Genetics’ Earnings Call Highlights Growth and OptimismAugust 4, 2025 | theglobeandmail.comFulgent Genetics (NASDAQ:FLGT) Announces Quarterly Earnings ResultsAugust 3, 2025 | marketbeat.comFulgent Genetics (NASDAQ:FLGT) Shares Gap Up After Better-Than-Expected EarningsAugust 3, 2025 | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Shares Gap Up After Earnings BeatAugust 2, 2025 | marketbeat.comFulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2025 Earnings Call TranscriptAugust 2, 2025 | insidermonkey.comFulgent Genetics (NASDAQ:FLGT) Updates FY 2025 Earnings GuidanceAugust 2, 2025 | marketbeat.comFulgent (FLGT) Q2 Revenue Jumps 16%August 2, 2025 | fool.comWhy Fulgent Genetics Stock Was Crushing It on FridayAugust 1, 2025 | fool.comFulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | seekingalpha.comFulgent Genetics, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 1, 2025 | seekingalpha.comFulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue EstimatesAugust 1, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLGT Company DescriptionsFulgent Genetics NASDAQ:FLGT$20.36 -0.05 (-0.24%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$20.35 -0.01 (-0.05%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.